Among the most intriguing compounds to emerge from Soviet-era neuroscience, Semax and Selank occupy a unique place in the peptide research landscape. Both were developed in Russia, both act on the central nervous system, and both continue to attract significant interest from researchers studying cognition, neuroplasticity, and anxiety-related pathways. Yet despite their shared origins, these two peptides have markedly different mechanisms and research profiles.
This guide compares Semax and Selank across their molecular structures, proposed mechanisms of action, published study contexts, stability characteristics, and practical considerations for UK-based researchers sourcing them for laboratory use.
Both compounds were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Semax was derived from the adrenocorticotropic hormone (ACTH) fragment 4–7, extended with additional amino acids to improve stability and potency. Selank, meanwhile, was engineered from the endogenous neuropeptide tuftsin (Thr-Lys-Pro-Arg), a tetrapeptide known for its immunomodulatory and anxiolytic properties in animal models.
Both peptides have been investigated in Russian clinical contexts — Semax has been used in some Eastern European countries as a nasal spray for cognitive and neurological applications — but for the purposes of UK research procurement, both are classified strictly as research compounds for in vitro and laboratory use only.
Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is an analogue of the ACTH(4-10) fragment, modified to resist enzymatic degradation. The compound is typically encountered as a lyophilised powder with a molecular weight of approximately 813 Da.
One of the most studied aspects of Semax in preclinical research is its apparent ability to modulate brain-derived neurotrophic factor (BDNF) expression. Studies in rodent models have demonstrated upregulation of BDNF and its receptor TrkB following Semax administration, with researchers proposing this as a potential mechanism for observed improvements in learning and memory tasks.
Research has also examined Semax's interaction with monoamine systems. Several in vivo studies in rats report changes in dopamine and serotonin turnover in limbic regions following administration, suggesting potential relevance for mood-related research models. It is worth noting that these are preclinical findings and do not constitute evidence of efficacy in humans.
A notable thread in Semax research involves ischaemic injury models. Studies published in Russian and Eastern European journals have explored Semax administration in models of cerebral ischaemia, reporting reductions in infarct size and improvements in neurological scores in treated animals. These studies have informed hypothesis generation in the broader neuroprotection research field.
In published rodent studies, Semax has typically been administered intranasally or subcutaneously in ranges of 50–300 mcg/kg. These figures are provided strictly as literature reference points for researchers designing in vitro or animal study protocols.
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin with additional Pro-Gly-Pro residues added to enhance metabolic stability. Its molecular weight is approximately 863 Da. The addition of the Pro-Gly-Pro tripeptide significantly extends its half-life compared to native tuftsin.
The primary research focus for Selank has been its anxiolytic-like effects in animal models. Studies using elevated plus maze, open field, and forced swim tests have consistently found Selank-treated rodents exhibiting behaviours consistent with reduced anxiety, without the sedative profile observed with benzodiazepines in the same models. Researchers have proposed GABAergic modulation as one contributory mechanism, though the precise pathway remains an area of active investigation.
A distinctive feature of Selank's pharmacology, as described in the literature, is its interaction with enkephalin-degrading enzymes. Selank appears to inhibit the enzymatic breakdown of met-enkephalin, thereby potentiating endogenous opioid activity without directly binding opioid receptors. This has made it of particular interest in research exploring anxiolysis without dependence risk.
Consistent with its tuftsin ancestry, Selank has also been studied for its effects on immune function. Rodent studies have reported changes in interleukin profiles and T-cell activity following Selank administration, positioning it as a compound of potential interest in neuroimmunology research.
Interestingly, some published studies have also reported BDNF modulation with Selank, creating an area of mechanistic overlap with Semax. However, the downstream functional differences between the two suggest that BDNF upregulation, if present, operates through distinct upstream pathways in each compound.
| Feature | Semax | Selank |
|---|---|---|
| Origin peptide | ACTH(4-7) | Tuftsin |
| Primary research focus | Cognition, neuroprotection | Anxiolysis, immunomodulation |
| Key mechanism | BDNF upregulation, monoamine modulation | Enkephalinase inhibition, GABAergic activity |
| Molecular weight | ~813 Da | ~863 Da |
| Typical study admin route | Intranasal / subcutaneous | Intranasal / subcutaneous |
| Immunomodulatory data | Limited | Significant |
Both Semax and Selank are supplied as lyophilised powders and share broadly similar storage requirements, though researchers should note a few distinctions.
In their lyophilised form, both peptides are stable at 2–8°C for extended periods (typically up to 24 months when properly sealed and refrigerated). For longer-term archival storage, both can be kept at -20°C with minimal degradation risk. They should be protected from light and moisture at all times.
Once reconstituted in bacteriostatic water, both peptides should be stored at 2–8°C and used within 4 weeks. Avoid repeated freeze-thaw cycles, as this can accelerate degradation. Selank is generally considered slightly more susceptible to degradation upon reconstitution than Semax, owing to its tuftsin-derived sequence being a natural substrate for peptidases.
For researchers working with small aliquots, it is advisable to divide reconstituted peptide into single-use volumes and freeze unused portions immediately rather than repeatedly drawing from the same vial.
When sourcing either Semax or Selank for laboratory research in the UK, purity is the critical variable. Both peptides have complex sequences that are susceptible to truncation, oxidation, or sequence errors during synthesis. Key quality indicators to look for include:
At Monumental Peptides, both Semax and Selank are supplied as research-grade lyophilised powders with full CoA documentation available upon request. All products are for in vitro and laboratory research use only.
The choice between Semax and Selank depends entirely on the research question being investigated:
Some researchers choose to include both compounds in parallel arms of a study to explore whether their effects are additive, synergistic, or independent — a legitimate and productive research design given their mechanistic differences.
Semax is primarily researched for its cognitive-enhancing and neuroprotective properties, with studies focusing on BDNF upregulation and monoamine modulation. Selank is primarily researched for its anxiolytic-like effects in animal models, mediated partly through enkephalinase inhibition and GABAergic pathways. Both are for in vitro and laboratory research use only.
Yes, some researchers include both compounds in parallel study arms to compare their effects or explore potential interactions. Their distinct mechanisms make this a valid comparative research design. All research should comply with institutional ethics and regulatory requirements.
Both peptides should be stored as lyophilised powder at 2–8°C (refrigerator) or -20°C for long-term archival. Once reconstituted in bacteriostatic water, store at 2–8°C and use within 4 weeks. Protect from light and avoid repeated freeze-thaw cycles.
Monumental Peptides supplies research-grade Semax and Selank to UK-based researchers. Both are available as lyophilised powders with Certificate of Analysis documentation. Visit our Semax and Selank product pages for current availability and pricing. For laboratory research use only.
Research-grade Semax and Selank should have HPLC purity of ≥98%, with mass spectrometry confirmation of the correct molecular weight. Always request a batch-specific Certificate of Analysis from your supplier before use in any research protocol.